Cost ‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
ConclusionsThis analysis suggests that adding empagliflozin to SoC in HF patients with T2D constitutes a cost ‐effective use of UK healthcare resources and may provide long‐term health benefits to patients.
Source: ESC Heart Failure - Category: Cardiology Authors: Odette S. Reifsnider,
Anuraag R. Kansal,
Jennifer Franke,
Joseph Lee,
Jyothis T. George,
Martina Brueckmann,
Stefan Kaspers,
Sarah B. Brand,
Anastasia Ustyugova,
Stephan Linden,
Matthew Stargardter,
Nikco Hau Tags: Original Research Article Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Heart Attack | Heart Failure | Jardiance | Stroke | Study